Lmr Partners LLP Madrigal Pharmaceuticals, Inc. Transaction History

Lmr Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $5.1 Million - $8.43 Million	-29,777 Reduced 57.39%	22,108 $5.9 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $5.34 Million - $10.5 Million	44,385 Added 591.8%	51,885 $12 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $1.1 Million - $1.69 Million	7,500 New	7,500 $1.1 Million
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $339,730 - $391,876	-3,130 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $344,487 - $418,480	3,130 New	3,130 $348,000

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.